Financing ·
On June 15, 2026, Alvotech notified Jefferies LLC of the suspension and termination of its ATM Prospectus Supplement…
ALVOAlvotech
On June 15, 2026, Alvotech notified Jefferies LLC of the suspension and termination of its ATM Prospectus Supplement related to the issuance of ordinary shares under the Open Market Sale Agreement dated June 14, 2024. The company will not sell securities under this agreement until a new prospectus supplement or registration statement is filed, though the Sales Agreement itself remains in effect. Alvotech is a biopharmaceutical company that develops and manufactures biosimilar medicines.